IGC Pharma, Inc.
IGC- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001326205
No open-market purchases or sales by IGC Pharma, Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $1.43M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by IGC Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for IGC Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Mukunda Ram | CEO | 6,875,563 | Jul 1, 2026 | 4 |
| Grimaldi Claudia | PFO | 3,421,092 | Jul 1, 2026 | 3 |
| Prins Richard K | Director | 1,541,251 | Apr 6, 2026 | 3 |
| Moran James P | Director | 1,235,735 | Apr 6, 2026 | 2 |
| Lierman Terry L | Director | – | Oct 21, 2025 | 1 |
| Bradbury Strategic Investment Fund A (Cayman Islands Registration No. CR-359857) | 10% Owner | 13,823,529 | May 13, 2024 | 0 |
| LYNCH John Edward | Director | 134,401 | Jun 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 27, 2024 (view filing)4:05 PM ET | Sep 25 | 2 days | Moran James PDirector | PPurchase | +588.2K | $0.34 | +$200.0K | +166.1%942.4K after |